By Gregg A. Masters, MPH
This clip courtesy of The Oncologist (follow via @OncJournal):
The timely session considers the question: ‘What answer in context is the biomarker result(s) intended to inform? How can or will it impact treatment decisions?
‘if we’re going to move forward it is essential that we can actually make measurements that are going mean something..’
Faculty: Howard I. Scher, MD, Chief, Genitourinary Oncology Service; D. Wayne Calloway Chair in Urologic Oncology, Memorial Sloan Kettering Cancer Center (follow via @Sloan_Kettering).